Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesCharles River Laboratories

Charles River Laboratories

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
342.69 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
834901
Market Cap
9034.51M

Momentum Score

…

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
342.25
Low
356.00
High
52 Week Price Range
108.10
Low
228.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Charles River Laboratories provides preclinical, safety assessment and laboratory services to pharmaceutical, biotech and academic customers worldwide, supporting early-stage drug discovery through nonclinical and clinical work. Long-term growth may be supported by secular R&D outsourcing and rising biologics and cell/gene therapy development, and investors may find the company attractive for its scale, diversified services and global network.

Major risks include regulatory and reputational pressure around animal testing, sensitivity to pharmaceutical R&D cycles, competitive and pricing pressure, and execution and leverage risks from acquisitions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
342.69
Dividend Yield
-
Revenue TTM
4015.38M
Revenue Per Share
81.01
Gross Profit TTM
1404.64M
Debt / Equity
0.97
ROE
-4.23%
Net Debt
2851.74M
ROCE
8.44%
Diluted EPS TTM
-2.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -99.50M 93.11M 581.28M 622.99M 480.71M
Minority interest -2.17M -3.09M -5.57M 6.38M 7.86M
Net income -144.34M 10.30M 474.62M 486.23M 390.98M
Selling general administrative 723.42M 751.00M 750.35M 665.10M 619.92M
Gross profit 1225.57M 1331.82M 1502.56M 1462.65M 1334.64M
Reconciled depreciation 403.31M 361.74M 311.15M 303.87M 265.54M
Ebit 507.84M 219.40M 717.99M 650.98M 589.86M
Ebitda 911.15M 581.14M 1032.12M 986.15M 820.16M
Depreciation and amortization 403.31M 361.74M 314.12M 335.17M 230.30M
Non operating income net other - - - 31.30M -35.24M
Operating income 507.84M 227.35M 617.26M 650.98M 589.86M
Other operating expenses 3507.54M 3822.64M 3512.15M 3325.09M 2950.30M
Interest expense 107.03M 126.29M 136.71M 59.29M 73.91M
Tax provision 42.66M 67.82M 136.97M 130.38M 81.87M
Interest income 126.99M 8.57M 3.95M 0.78M 74.86M
Net interest income -102.09M -117.71M -134.00M -58.51M -73.26M
Income tax expense 42.66M 67.82M 100.91M 130.38M 81.87M
Total revenue 4015.38M 4049.99M 4129.41M 3976.06M 3540.16M
Total operating expenses 717.73M 1104.47M 885.29M 811.68M 744.78M
Cost of revenue 2789.81M 2718.17M 2626.85M 2513.41M 2205.52M
Total other income expense net -607.34M -134.23M -35.98M -27.99M -109.15M
Net income from continuing ops -142.16M 25.29M 480.52M 492.61M 398.84M
Net income applicable to common shares -144.34M 10.30M 474.62M 486.23M 390.98M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 7135.42M 7528.35M 8195.00M 7602.77M 7024.29M
Intangible assets 340.00M 723.40M 864.05M 955.27M 1061.19M
Other current assets 224.65M 209.01M 171.26M 107.58M 97.31M
Total liab 3924.23M 4020.27M 4536.00M 4579.27M 4432.30M
Total stockholder equity 3164.63M 3461.50M 3596.88M 2976.29M 2534.82M
Deferred long term liab - - - 215.58M 239.72M
Other current liab 700.04M 605.44M 605.52M 621.41M 612.56M
Common stock 0.49M 0.51M 0.51M 0.51M 0.51M
Capital stock 0.49M 0.51M 0.51M 0.51M 0.51M
Retained earnings 1388.62M 1812.10M 1887.22M 1432.90M 980.75M
Other liab - - - 390.40M 482.58M
Good will 2764.25M 2846.61M 3095.05M 2849.90M 2711.88M
Other assets 360.52M 320.41M 349.66M 0.00M -47.21M
Cash 213.77M 194.61M 276.77M 233.91M 241.21M
Cash and equivalents 213.77M 194.61M 276.77M 233.91M 241.21M
Total current liabilities 1120.32M 994.10M 1055.08M 1091.59M 1033.18M
Current deferred revenue 210.42M 248.32M 241.82M 264.26M 219.70M
Net debt 2851.74M 2529.39M 2789.61M 2863.36M 2678.12M
Short term debt 61.06M 114.02M 441.12M 0.00M 2.79M
Short long term debt - - - - 0.10M
Short long term debt total 3065.51M 2723.99M 3066.38M 3097.28M 2919.33M
Other stockholder equity 1947.30M 1966.24M 1905.58M 1804.94M 1718.30M
Property plant equipment 2016.63M 2016.50M 2033.77M 1857.42M 1584.01M
Total current assets 1447.05M 1403.07M 1608.66M 1439.03M 1274.10M
Long term investments 206.97M 218.35M 243.81M 311.60M 201.35M
Net tangible assets - - - -786.46M -1185.24M
Short term investments - 0.06M 0.07M 1.00M 1.06M
Net receivables 708.86M 720.91M 780.38M 752.39M 642.88M
Long term debt 2111.71M 2240.20M 2647.15M 2707.53M 2639.03M
Inventory 299.10M 278.54M 380.26M 255.81M 199.15M
Accounts payable 148.80M 140.34M 168.94M 205.91M 198.13M
Noncontrolling interest in consolidated entity - - - 4.79M 4.16M
Accumulated other comprehensive income -171.78M -317.35M -196.43M -262.06M -164.74M
Common stock total equity - - - 0.51M 0.51M
Retained earnings total equity - - - 1432.90M 980.75M
Non currrent assets other 293.19M 278.23M 309.38M 148.28M 151.54M
Non current assets total 5688.37M 6125.27M 6586.34M 6163.74M 5750.20M
Capital lease obligations 458.70M 483.79M 419.23M 389.75M 316.16M
Long term debt total 2136.36M 2240.20M 2647.15M 2707.53M 2663.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -10.97M -245.09M -280.40M -153.72M -39.02M
Change to liabilities - - - -44.82M 89.20M
Total cashflows from investing activities -209.32M -245.09M -563.15M -607.92M -1437.93M
Net borrowings -121.78M -412.19M -75.32M 19.79M 669.98M
Total cash from financing activities -536.73M -550.93M -85.52M -42.40M 672.60M
Change to operating activities - - - -8.92M 46.31M
Net income -142.16M 25.29M 480.37M 492.61M 398.84M
Change in cash 10.43M -78.91M 43.27M -5.10M 13.20M
Begin period cash flow 205.57M 284.48M 241.21M 246.31M 233.12M
End period cash flow 216.00M 205.57M 284.48M 241.21M 246.31M
Total cash from operating activities 737.65M 734.58M 683.90M 619.64M 760.80M
Depreciation 403.31M 361.74M 314.12M 303.87M 265.54M
Other cashflows from investing activities 20.80M 4.55M -2.29M -129.46M -1170.14M
Dividends paid - - 25.60M - -
Change to inventory -48.78M 16.80M -62.30M -78.52M -25.16M
Change to account receivables 35.74M 21.61M -33.43M -150.57M -26.63M
Sale purchase of stock -360.67M -119.17M -24.16M -38.65M -40.71M
Other cashflows from financing activities -54.98M -19.56M 13.96M 2903.78M 6956.18M
Change to netincome - - - -51.06M 23.06M
Capital expenditures 219.15M 232.97M 318.53M 324.73M 228.77M
Change receivables - - - -150.57M -26.63M
Cash flows other operating - - - 148.13M 35.95M
Cash and cash equivalents changes - - - -30.68M -4.54M
Change in working capital 14.08M -30.33M -102.38M -152.55M 42.94M
Stock based compensation 71.08M 69.89M 72.05M 73.62M 71.47M
Other non cash items 466.62M 375.41M -29.36M -62.02M 6.01M
Free cash flow 518.49M 501.61M 365.37M 294.91M 532.03M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CRL
Charles River Laboratories		 -
-%		 342.69 - 16.47 2.25 2.85 2.84 27.73
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Charles River Laboratories

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

251 Ballardvale Street, Wilmington, MA, United States, 01887

781 222 6000

https://www.criver.com

18300

Name Title Year Born
Mr. James C. Foster J.D. Chairman, CEO & Pres 1951
Ms. Birgit Girshick Corp. Exec. VP & COO 1970
Mr. Joseph W. LaPlume Corp. Exec. VP of Corp. Devel. & Strategy 1974
Mr. William D. Barbo Chief Commercial Officer & Corp. Exec. VP 1961
Mr. David Ross Smith Sr. Financial Advisor 1966
Ms. Flavia H. Pease Corp. Exec. VP & CFO NA
Mr. Michael Gunnar Knell Corp. Sr. VP & Chief Accounting Officer 1977
Prof. Julie Frearson Ph.D. Corp. Sr. VP & Chief Scientific Officer NA
Mr. Mark Mintz Corp. Sr. VP & Chief Information Officer NA
Todd Spencer Corp. VP of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…